Is the success rate of IVF in Thailand real? – An objective analysis based on clinical data and patient conditions
Reproductive Doctor's Perspective Clinical Decision Logic Real Data Interpretation
In the reproductive clinic, I meet patients every day who come for consultation holding promotional materials about IVF in Thailand. Their most pressing question is: The success rates of IVF in Thailand are so high, are they real? As a doctor, my answer is usually — the data itself has reference value, but it must be interpreted within the context of your personal fertility conditions. At the same hospital, the difference in success rates between a 35-year-old and a 42-year-old patient can be more than threefold. Discussing success rates without considering age, ovarian reserve, and embryo chromosomal status is meaningless.
1. Are the success rate data for IVF in Thailand real?
Whether the success rate data for IVF in Thailand is real depends on three dimensions: statistical methodology, patient selection, and age stratification. Currently, most reproductive centers in Thailand publish success rates calculated as the "clinical pregnancy rate per single frozen embryo transfer after PGT-A screening in women under 35", which typically ranges between 55% and 65%. However, if you are over 40, have low ovarian reserve, or do not use PGT-A, this data has limited reference value for you.
Core Judgment: The success rate data for IVF in Thailand is not false in itself, but there is a problem of "misalignment between data metrics and patient conditions." The data published by hospitals is more suitable as a reference indicator of laboratory quality rather than a predictor of individual success.
2. Why are success rate data controversial?
There are three main reasons why success rate data is questioned:
- Inconsistent statistical methodology: Some centers calculate based on "transfer cycles," others on "egg retrieval cycles," and still others on "number of patients." Different denominators lead to significant percentage differences.
- Patient selection bias: Some centers may select younger patients with good ovarian function for their statistics, excluding older or complex cases from the "success rate calculation."
- Individual differences are ignored: Hospitals publish group averages, but each patient's ovarian reserve, uterine conditions, and embryo chromosomal status are completely different. Group data cannot be directly applied to an individual.
3. Real success rate differences across age groups
Age is the most critical factor affecting IVF success rates, bar none. The following data is based on stratified statistics from mainstream reproductive centers in Thailand (live birth rate per single frozen embryo transfer after PGT-A screening) and aligns with the consensus range of international reproductive medicine:
| Age Group | Live Birth Rate per Transfer after PGT-A | Live Birth Rate per Transfer without PGT-A | Data Reliability |
|---|---|---|---|
| < 35 years | 55%–65% | 40%–50% | High, large sample size |
| 35–37 years | 45%–55% | 35%–42% | High |
| 38–40 years | 30%–40% | 22%–30% | Moderate, increased individual variation |
| 40–42 years | 20%–30% | 12%–18% | Relatively low, needs consideration of embryo status |
| 43–45 years | 5%–10% | 3%–5% | Low, comprehensive evaluation recommended |
Note: The "live birth rate" in the table above refers to the proportion of live births per single transfer, not the "clinical pregnancy rate." Some centers publish the "clinical pregnancy rate" (i.e., seeing a gestational sac on ultrasound), which is typically 5-8 percentage points higher than the live birth rate.
4. Differences in conditions across hospitals
Laboratory conditions, embryo culture techniques, and PGT-A capabilities vary among different reproductive centers in Thailand, and these factors directly impact success rates:
- Laboratory hardware: The stability of embryo incubators, air quality (VOC control), and culture media quality control systems are fundamental conditions determining whether embryos can develop to the blastocyst stage.
- Embryologist experience: ICSI procedures, blastocyst biopsies, and cryopreservation/thawing techniques depend on the skill level of the embryologist. An inexperienced team may lead to embryo damage or thawing failure.
- PGT-A testing platform: NGS and aCGH platforms differ in resolution and detection rates, affecting the accuracy of embryo chromosomal screening.
To assess the laboratory quality of a center, look at two indicators: blastocyst formation rate (should normally reach 50%-60%) and frozen embryo survival rate (should normally be > 95%).
5. The most easily overlooked detail: What is the denominator?
When reading success rate data, the first question to ask is: What is the denominator?
- Calculated per "transfer cycle": The denominator is the number of completed transfers, excluding cycles where no embryos were available for transfer. This data is usually the highest.
- Calculated per "egg retrieval cycle": The denominator is the number of cycles started for ovarian stimulation, including cycles with failed egg retrieval, failed fertilization, or no usable embryos. This data is closer to the real experience.
- Calculated per "number of patients": The denominator is the number of patients who visited, including those who dropped out or transferred to another hospital. This data is the most realistic, but few centers publish it.
Example: A center publishes a "clinical pregnancy rate per transfer cycle of 62%," but if calculated per "egg retrieval cycle," it might be only 42%-48%, because not every egg retrieval cycle yields a transferable embryo. Both figures are real, but they represent different meanings.
6. Relationship between key examination indicators and success rates
The following indicators can help you more accurately assess your own success rate range, rather than just looking at the hospital's published average data:
| Indicator | Reference Range | Impact on Success Rate |
|---|---|---|
| AMH (Anti-Müllerian Hormone) | > 1.2 ng/mL | Lower AMH means fewer eggs retrieved and lower cumulative live birth rate. When AMH < 0.5 ng/mL, the live birth rate per egg retrieval cycle is significantly reduced. |
| FSH (Follicle-Stimulating Hormone) | < 10 IU/L | Elevated FSH suggests diminished ovarian reserve and may indicate a poor response to ovarian stimulation medication. |
| Antral Follicle Count (AFC) | > 8 | AFC directly reflects the number of recruitable follicles in the ovaries and is positively correlated with the number of eggs retrieved. |
| Embryo Chromosomal Normality Rate | ~55%–65% under 35 | The rate of chromosomal normality decreases with age, dropping to 20%–30% after 40, and is a core factor affecting transfer success. |
| Endometrial Thickness | 7–14 mm | Too thin (< 6 mm) or too thick (> 16 mm) may affect embryo implantation. |
7. When are Thailand IVF success rate data useful for you?
Thailand IVF success rate data has good reference value under the following conditions:
- Age under 35, with AMH and AFC within normal ranges, and no uterine structural abnormalities.
- Planning to use PGT-A screening, transferring embryos that have undergone chromosomal screening (euploid).
- Choosing a center with mature laboratory conditions and an independent embryology team, rather than just based on promotional materials.
- Can accept the concept of cumulative live birth rate over 2-3 egg retrieval cycles, rather than just the success rate per single transfer.
Under the following conditions, the reference value of Thailand IVF success rate data is limited:
- Age over 40, with low ovarian reserve (AMH < 0.8 ng/mL).
- History of recurrent implantation failure, recurrent miscarriage, or uterine structural abnormalities.
- Not using PGT-A screening, transferring embryos without chromosomal screening.
- Unable to complete more than 2 egg retrieval cycles (cumulative live birth rate per single cycle is limited).
Summary Judgment: Thailand IVF success rate data is real, but it is a "group probability" rather than a "personal prediction." Your personal success rate needs to be comprehensively assessed based on five dimensions: age, AMH, AFC, embryo chromosomal status, and uterine conditions. It is recommended to ask the hospital for age-stratified live birth rate data during consultation, rather than overall average data.
8. How clinicians judge success rates
In clinical decision-making, doctors typically do not directly cite a hospital's published success rate data. Instead, they assess along the following path:
- Step 1: Determine ovarian reserve category (high response, normal response, low response) based on the patient's age, AMH, and AFC.
- Step 2: Based on previous ovarian stimulation history (if any), determine the medication response pattern and estimate the range of eggs to be retrieved.
- Step 3: Based on age and the embryo chromosomal normality curve, estimate the number of euploid embryos obtainable per egg retrieval cycle.
- Step 4: Combine uterine conditions and previous transfer history to estimate the implantation probability per single transfer.
- Step 5: Integrate the above information to provide an estimate of the "cumulative live birth rate per egg retrieval cycle," rather than the success rate per single transfer.
This evaluation process is independent of the hospital's published success rate data and is entirely based on the patient's individual parameters. If you go for a consultation and a doctor tells you "the success rate is 60%" without asking about your AMH and age, the reference value of that data should be viewed with caution.
9. Common pitfalls
- Confusing "clinical pregnancy rate" with "live birth rate": The clinical pregnancy rate includes cases of biochemical pregnancy and early miscarriage; the live birth rate is the final outcome. The difference between the two is 5-10 percentage points.
- Ignoring the risk of "no embryos available": Some patients (especially older women or those with low AMH) may face failed fertilization, failed blastocyst culture, or no euploid embryos after PGT-A screening. These cycles with "no embryos available" are not counted in the transfer success rate.
- Assuming "success on the first try" is the norm: Even under optimal conditions (under 35, normal AMH, transfer after PGT-A screening), the live birth rate per single transfer is only about 60%, meaning 40% of patients will need a second or third transfer.
- Being misled by "success stories": Success stories online are often selected, while failure cases are rarely shared publicly. Survivorship bias can lead you to overestimate the success rate.
10. Actual process and timeline
The complete process for IVF in Thailand typically includes the following stages. The timing of each stage affects the overall number of cycles and cumulative success rate:
| Stage | Time | Notes |
|---|---|---|
| Pre-departure examinations in home country | 2-4 weeks | AMH, FSH, AFC, semen analysis, infectious disease screening, chromosomal testing |
| Ovarian stimulation and egg retrieval | 12-16 days | Requires setting aside a full cycle period in Thailand |
| Blastocyst culture and PGT-A | 3-4 weeks | Waiting for embryo biopsy and genetic test results |
| Frozen embryo transfer | 1-2 weeks | Must be performed during the endometrial window; usually requires 5-7 days of medication to prepare the lining |
| Pregnancy test after transfer | 10-12 days after transfer | Blood test for β-hCG |
If no transferable euploid embryo is obtained from one egg retrieval cycle, repeated ovarian stimulation cycles are needed. It is recommended to wait 2-3 months between cycles to allow the ovaries to fully recover.
11. Risk reminders
Risks to be aware of:
- Ovarian Hyperstimulation Syndrome (OHSS) – Higher risk for patients with Polycystic Ovary Syndrome (PCOS); requires doctor assessment for prevention plan.
- Embryo chromosomal abnormalities – The older the age, the lower the rate of normal embryo chromosomes, a major cause of transfer failure and miscarriage.
- Variation in laboratory and embryologist standards – Blastocyst formation rates, biopsy success rates, and survival rates differ between centers, directly affecting the number of usable embryos.
- Policy and compliance risks – Policies related to assisted reproduction in Thailand may change; confirm current regulations before starting.
- Financial risk – The cost per cycle is high (approximately 80,000-150,000 RMB). If no transferable embryo is obtained, the fee is non-refundable.
12. Examination reminders and time planning
If you are planning to undergo IVF in Thailand, it is recommended to complete the following examinations in your home country beforehand so that the doctor can assess your baseline conditions:
- Female: AMH, FSH, LH, E2, P, TSH, Antral Follicle Count (ultrasound), saline infusion sonohysterography (if uterine abnormality suspected).
- Male: Semen analysis, sperm morphology, sperm DNA fragmentation index (DFI), infectious disease screening.
- Both partners: Karyotype analysis, Thalassemia screening (recommended for individuals from Southern China), four infectious disease markers.
The validity of the above tests is usually 6-12 months; some items (like karyotype) are valid for life. It is recommended to complete the tests within 3 months before the planned start date to ensure the data is usable for the doctor's decision-making.
This article is compiled based on clinical consensus in reproductive medicine and publicly available research data, aiming to provide objective knowledge reference and does not constitute medical advice or treatment promises. Individual conditions vary greatly; please consult a licensed reproductive medicine doctor for specific diagnosis and treatment plans.
